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ABSTRACT
Association of Mycobacterium avium subspecies paratuberculosis (MAP) with
Crohn’s disease (CD) and not with ulcerative colitis (UC), two forms of inflammatory
bowel disease (IBD), has been vigorously debated in recent years. This theory has been
strengthened by recent culture of MAP from breast milk, intestinal tissue and Blood from
patients with active Crohn’s disease. Culture of MAP from clinical samples remained
challenging due to the fastidious nature of MAP including its lack of cell wall in infected
patients. The advent of real time PCR has proven to be significant in infectious disease
diagnostics. In this study, real time reverse transcriptase PCR (RT-PCR) assay based on
targeting mRNA of the IS900 gene unique to MAP has been developed. All variables
included in RNA isolation, cDNA synthesis and real time PCR amplification have been
optimized. Oligonucleotide primers were designed to amplify 165 bp specific to MAP
and the assay demonstrated sensitivity of 4 genomes per sample. In hope this real time
RT-PCR may aid in the detection of viable MAP cells in Crohn’s disease patients, a total
of 45 clinical samples were analyzed. Portion of each sample was also subjected to 12
weeks culture followed by standard nested PCR analysis. The samples consisted of 17
cultures (originated from 13 CD, 1 UC and 3 NIBD subjects), 24 buffy coat blood
(originated from 7 CD, 2 UC, 11 NIBD and 4 healthy subjects) and 4 intestinal biopsies
from 2 CD patients. Real time RT-PCR detected viable MAP in 11/17 (65%) of
iii

suspected cultures compared to 12/17 (70%) by nested PCR including 77% and 84%
from CD samples by both methods, respectively. Real time RT-PCR detected MAP RNA
directly from 3/7 (42%) CD, 2/2 (100%) UC and 0/4 healthy controls similar to results
following long term culture incubation and nested PCR analysis. Interestingly, real time
RT-PCR detected viable MAP in 2/11 (13%) compared to 4/11 (26%) by culture and
nested PCR in NIBD patients. For tissue samples, real time RT-PCR detected viable
MAP in one CD patient with the culture outcome remains pending. This study clearly
indicates that a 12-hr real time RT-PCR assay provided data that are similar to those from
12 weeks culture and nested PCR analysis. Consequently, use of real time In our
laboratory, we previously demonstrated a possible downregulation in the Interferongamma receptor gene (IFNGR1) in patients with active Crohn’s disease using microarray
chip analysis. In this study, measurement of RNA by real time qRT-PCR indicated a
possible downregulation in 5/6 CD patients compared to 0/12 controls. The preliminary
data suggest that downregulation in INFGR1 gene, and the detection of viable MAP in
CD patients provides yet the strongest evidence toward the linkage between MAP and
CD etiology.
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CHAPTER ONE: INTRODUCTION
Crohn’s disease (CD) is known to be an important cause of gastrointestinal disease
worldwide but occurring more frequently in the United States, United Kingdom and
Scandinavia (19). CD can affect any part of the gastrointestinal tract; inflammation is
discontinued in form of patches and transmural resulting in fistula formation, the most
common location is the ileum and small bowel (32). CD is present in two distinct forms:
perforating and non-perforating in clear analogy to two other mycobacterial diseases,
leprosy and tuberculosis (27, 33, 43). The etiology of CD remains unknown; however
granuloma and pathologic manifestations resemble aspects found in mycobacteria-caused
diseases such as tuberculosis, leprosy and paratuberculosis (16, 27, 53, 8).
Mycobacterium avium subspecies paratuberculosis (MAP) has been reported as
possible causative agent for CD, due to the very important similarities in symptoms and
aspect of the disease with Johne’s disease, an inflammatory bowel disease in ruminants
caused by MAP; Association of Map with CD was first sighted by Dalziel in 1913 and
has got more attention recently when MAP was isolated from blood, gut, lymphoid tissue,
and milk of CD patients (7, 46, 47).
MAP is a member of the Mycobacterium avium complex (MAC), it is well
characterized by its acid fastness, slow growing rate and resistance to acid and alcoholic
treatments (14) as well as to regular pasteurization techniques this meanly due to their
1

cell-wall rich in lipid and long chain peptidoglycans. MAP is considered very fastidious
and requires long-term incubation during primary isolation from animal and human
sources (47, 48, 52).
The role of MAP in CD has been controversial and was debated vigorously;
isolation of MAP from clinical samples of CD patients has been inconsistent adding to
the controversy. This is mainly due to the fastidious nature of MAP, its presence in
Spheroplastic form in CD patients and to its slow growing nature, culture of MAP from
clinical samples may take between 12 and 52 weeks. A new strategy of study is needed to
investigate the role of MAP in CD etiology.
It had been reported that mutations in NOD2/ CARD15 gene are associated
exclusively with CD (31; 35, 49) identifying the gene as the first susceptibility gene for
Crohn’s disease NOD2 is expressed as cytoplasmic protein in monocytes, and includes a
C-terminus leucine-rich repeat (LRR) domain that senses muramyl dipeptide (MDP), the
minimal motif of bacterial cell wall peptidoglycan, suggesting a role for intracellular
pathogen-host interactions in the etiology of the disease.
In previous study, An RNA Microarray analysis of the expression profile of genes
from CD and UC patients using the buffy coats from peripheral blood had shown that
IFNGR1 (interferon-gamma receptor) gene, which encodes the ligand-binding chain of
the IFN-gamma receptor, is Downregulated exclusively in CD patients. Early studies had
shown that deficiencies in IFNGR1 gene are associated with familial disseminated
atypical mycobacterial infection and disseminated BCG infection. Individuals carrying
these deficiencies have an immunologic defect predisposing them to infection with
2

mycobacteria (38, 39, 40).
In this study, we developed a novel real time RT-PCR to detect the presence of
viable MAP in blood samples from patients with CD, UC, NIBD and healthy controls as
described in Chapter 1. In chapter 2, these clinical samples were subjected to INFGR1
gene analysis using quantitative real time RT-PCR to evaluate the expression of IFNGR1
gene in an attempt to confirm the Microarray findings. Ultimately the study will provide
for the first time weather there is a link between the INFGR gene downregulation and
susceptibility to MAP infection in patients with active Crohn’s disease. If confirmed our
finding will add a strong argument to the role of MAP in CD etiology.
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CHAPTER TWO: RT-PCR FOR DETECTION OF VIABLE
MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS
IN BLOOD AND TISSUE FROM PATIENTS WITH CROHN’S
DISEASE

Summary

Association of Mycobacterium avium subspecies paratuberculosis (MAP) with
Crohn’s disease (CD) and not with ulcerative colitis (UC), two forms of inflammatory
bowel disease (IBD,) has been vigorously debated in recent years. This theory has been
strengthened by recent culture of MAP from breast milk, intestinal tissue and Blood from
patients with active Crohn’s disease. Culture of MAP from clinical samples remained
challenging due to the fastidious nature of MAP including its lack of cell wall in infected
patients. The advent of real time PCR has proven to be significant in infectious disease
diagnostics. In this study, real time reverse transcriptase PCR (RT-PCR) assay based on
targeting mRNA of the IS900 gene unique to MAP has been developed. All variables
included in RNA isolation, cDNA synthesis and real time PCR amplification have been
optimized. Oligonucleotide primers were designed to amplify 165 bp specific to MAP
and the assay demonstrated sensitivity of 4 genomes per sample. In hope this real time
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RT-PCR may aid in the detection of viable MAP cells in Crohn’s disease patients, a total
of 45 clinical samples were analyzed. Portion of each sample was also subjected to 12
weeks culture followed by standard nested PCR analysis. The samples consisted of 17
cultures (originated from 13 CD, 1 UC and 3 NIBD subjects), 24 buffy coat blood
(originated from 7 CD, 2 UC, 11 NIBD and 4 healthy subjects) and 4 intestinal biopsies
from 2 CD patients. Real time RT-PCR detected viable MAP in 11/17 (65%) of
suspected cultures compared to 12/17 (70%) by nested PCR including 77% and 84%
from CD samples by both methods, respectively. Real time RT-PCR detected MAP RNA
directly from 3/7 (42%) CD, 2/2 (100%) UC and 0/4 healthy controls similar to results
following long term culture incubation and nested PCR analysis. Interestingly, real time
RT-PCR detected viable MAP in 2/11 (13%) compared to 4/11 (26%) by culture and
nested PCR in NIBD patients. For tissue samples, real time RT-PCR detected viable
MAP in one CD patient with the culture outcome remains pending. This study clearly
indicates that a 12-hr real time RT-PCR assay provided data that are similar to those from
12 weeks culture and nested PCR analysis. Consequently, use of real time RT-PCR may
be significant in investigating the controversial role of MAP in CD pathogenesis.
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Introduction

Mycobacterium Avium subsp paratuberculosis (MAP), a member of the
Mycobacterium avium complex (MAC) belongs to the genus of Mycobacteria which is a
large group of high %G+C gram positive microorganisms including more than a 100
species. The mean characteristics of this bacterium is its acid fastness, slow growing rate
and resistance to acid and alcoholic treatments (14) as well as to regular pasteurization
techniques due to the complexity of their cell-wall rich in lipid and long chain
peptidoglycans. Unlike other Mycobacteria, MAP is the only Mycobacterium subspecies
that depend on the siderophore mycobactin for in vitro growth (9). MAP is considered
very fastidious and requires long-term incubation during primary isolation from animal
and human sources (47, 48, 52).
MAP is an opportunistic intracellular chronic pathogen, it was identified over 100
years ago as the causative agent of Paratuberculosis in ruminants (21), known also as
Johne’s disease (JD), an inflammatory disease that affect the gastrointestinal (GI) tract
and manifest as a severe weight loss, diarrhea, decrease in milk production and ultimately
may lead to the death of infected hosts (30). MAP infection in farm animals has great
economic impact with an estimated three billions dollars loss per year world wide (6, 25).
The resistance of MAP to standard pasteurization and its detection in drinking water have
6

alarmed Scientists of possible zoonotic potential and impact on humans.
The association of MAP with Crohn’s disease, a chronic inflammatory bowel
disease with significant histological and pathological similarities with JD (18, 21)
tuberculosis and sarcoidosis, has been suggested initially by Dalziel (16) but ruled out by
Crohn’s et al (15) and reemerged again following the culture of Spheroplastic (cell wall
deficient) form of MAP from mesenteric tissue from patients with Crohn’s disease
following several months of culture incubation (7). The association of MAP with Crohn’s
disease became more controversial due to the conflicting outcomes in all reported studies.
However, Schwartz et al (54) reported the development of modified 7H9 culture media,
known as Mycobacterial Growth Indicator Tube (MGIT) and the isolation of MAP from
intestinal tissue from Crohn’s disease patients following 10-12 weeks of incubation. This
was followed by the isolation of MAP from human milk (46) adding more evidence to
the similarity between MAP infection in animals and human hosts. The use of MGIT
culture media for rapid isolation and detection of MAP from human sources has been
recently confirmed by investigators in the United Kingdom (3) and most recently in the
united state. World-wide Interest in investigating MAP association in Crohn’s disease
pathogenesis has been recently stirred following the report of isolation of MAP from
human peripheral blood suggesting for the first time a bacteremic phase in Crohn’s
disease pathogenesis and possible systemic infection in patients with MAP infection (47).
Numerous studies have been done in an attempt to determine the role of MAP in
Crohn’s disease etiology, but the results were inconsistent which added to the
controversy of the association of MAP with the disease.
7

Due to the challenges in consistent detection of MAP in human clinical samples,
some investigators relied on serologic detection of anti-MAP IgG antibodies in sera from
Crohn’s disease patients. However, using Serological tests such as IDEXX which is
based on cytoplasmic proteins from MAP cultured from JD-animal resulted in detection
of anti-MAP IgG antibodies in sera from Crohn’s disease patients similar to sera from
patients with ulcerative colitis and normal controls (11). However, when recombinant
MAP proteins such as p35 and p36 proteins were used in an ELISA-based assay, MAP
antibodies were detected in the majority of sera from patients with Crohn’s disease and
significantly less in sera from patients with ulcerative colitis and normal subjects (45).
Most recently, MAP DNA has been detected directly in tissue samples from the majority
of Crohn’s disease patients by FISH (51) and nested PCR (1).
Despite the success in detection of MAP, MAP DNA, or MAP antibodies in tissue
or blood samples which added significant evidence toward MAP association in Crohn’s
disease pathogenesis, many in the gastroenterology community remained skeptics and
posted vigorous negative commentary (41, 43). The need for new methodology that can
associate viable MAP with Crohn’s disease may be the key to providing key evidence to
the link. In this study a reverse transcription (RT) PCR based on Oligonucleotides
primers derived from the IS900 specific to MAP has been developed using real time
PCR. This new and improved technology provides real time detection of MAP RNA
(indicating viability) in clinical samples from humans infected with MAP. Ultimately,
MAP can be detected, if present, in clinical samples with in 12 hours instead of 12 weeks
of culture incubation.
8

Materiel and Methods

All materials used in this study were prepared and processed aseptically inside
Biosafety cabinets dedicated for specific purpose.

Bacterial strains:

Clinical MAP strain Ben obtained and purified from CD tissue was used in this
study. Other microorganisms were also included such as Mycobacterium tuberculosis
strain H37Ra (ATCC 25177), Mycobacterium avium subspecies avium, Mycobacterium
smegmatis strain MC2155. All mycobacterial isolates were cultured in Bactec or the
MGIT culture media. Supplements including OADC (oleic acid-albumin-dextrosecatalase) and Mycobactin J (0.5 mg/mL) were added to media when MAP was cultured.

Patients Populations:

A total of 24 subjects were included in the study: 7 with Crohn’s disease, 2 with
ulcerative colitis, and 15 with non-inflammatory bowel disease (of which three were
healthy controls). Informed consent was obtained in accordance with institutional review
board regulations at the University of Florida, Gainesville Veterans Affairs Medical
9

Center, and the University of Central Florida. The diagnosis of Crohn’s disease or
ulcerative colitis was established on standard clinical, endoscopic, histological, and
radiographic criteria.

Clinical Samples:

One 4-mL whole blood sample drawn into sterile K2-EDTA Vacutainer tube was
obtained from every patient participating in the study. All samples were coded to conceal
the patient’s identity and the diagnosis. The samples were immediately processed in a
class II biosafety cabinet. The buffy coat layer from each tube was transferred into a
separate sterile RNase free tube containing 750ul of RNA later solution (Ambion,
California) and was used immediately for extraction of RNA. Surgically removed tissue
specimens were also recruited and used in this study. The tissue samples were stored in
empty sterile tubes and coded as described earlier. All clinical samples were stored on ice
and transferred to the laboratory with in 24 hours of collection. Blood and tissue samples
were processed immediately either for culture in Bactec and MGIT media (Becton
Dickinson) with supplements or used for direct isolation of RNA.
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Cultures:

Blood and tissue samples were cultured as described previously (47), a total of 14
cultured samples suspected of mycobacterial growth were analyzed by extraction of RNA
and real time RT-PCR analysis as described later. The concentration of microorganism
cells used in the specificity experiments was estimated using spectrophotometric
measurement of 500ul of each bacterial culture at O.D. 680 nm in Smartspec (BioRad,
CA)

RNA extraction:

Clinical MAP strain Ben was used in all experiments related to extraction of RNA,
cDNA and PCR analysis. Extraction of RNA was performed using an RNA isolation kit
from Qiagen (Qiagen, Valencia, CA) with some modifications as follows. A 500uL of
MAP culture (0,58CFU/mL) was centrifuged at 13,000 rpm (17400g) at 4oC for 3min.
Cell pellet was resuspended in 1 ml of lysis buffer. Cells were physically disrupted using
Fast-prep system and pro blue cap tubes at speed of 6.5 m/s for two cycles with each 45
Seconds (Qbiogene, CA). Cell lysate was then centrifuged at 13000 rpm (17400g) in 4 oC
for 5 min Supernatant was removed to a sterile 2-ml RNase free tube followed by the
addition of 1mL elution buffer. The mixture was poured into the column as described by
the manufacturer. RNA in eluted buffer was then mixed with two volumes of ethanol,
11

stored at -20 oC for 2 hours. Tubes were then centrifuged at 13000rpm (17400g) at 4 oC
for 15min. Nucleic acid pellet was then washed with 70% ethanol, dried in a speed
vacuum (BioRad, Hercules, CA ) and finally dissolved in 50uL Of DEPC
(Diethylpyrocarbonate) sterile water. DNA was removed by the addition of DNase
(2units/ul) and incubation at 37 oC for 30min. DNA removal was confirmed by agarose
gel electrophoresis. The concentrations of RNA solutions were measured at an O.D. 260
nm.

Reverse Transcription:

RNA extracted from MAP strain Ben was used as template during reverse
transcription and cDNA analysis. Superscript III reduced RNase H activity (envitrogen,
CA) was used and we followed the protocol described in the kit with some
modifications, we added 2pmole of oligonucleotide PrimersF1/R1, 200g of RNA and
10mM of dNTP mix into a sterile PCR tube, the mixture was heated at 65oC for 5min and
incubated on ice for 3min then we added the buffer, RNase inhibitor and the enzyme
(200units), we incubated the reaction mixture at 60oC for 45min then at 70 oC for 15 min
to inactivate the reaction.

12

Real time PCR:

cDNA obtained by reverse transcription was subject to real time PCR using Syber
green and MY IQ system (BioRad, Hercules, CA ).12.5ul of 2x SYBR Green (100mM
KCl, 40 mM Tris-HCl, pH8.4, 0.4mM of each dNTP, enzyme(50units/ml, 6mM Mgcl2,
SYBR Green I, fluorescein, and stabilizers) were added to sterile PCR tube as well as
Betaine, oligonucleotide primers (6pM), 2.5ul of cDNA and sterile water for a final
volume of 25ul.the PCR tubes were then subject to the following protocol: hot start step
of 5min at 95oC followed by20 sec at 95oC then 30 sec at 60oC for annealing, the
fluorescence reading was done at this step. Two set of primers were used, the first
set(Av1/Av2) amplify 280 base pair of MAP specific sequence IS900 and was used to
generate the standards while the second set(F1/R1) amplify 165 base pair within the 280
amplified by Av1/Av2
- Av1: 5’ ATGTGGTTGCTGTGTTGGATGG 3’
-

Av2: 5’CCGCCGCAATCAACTCCAG 3’

-

F1: 5’ CACGTCGGCGTGGTCGTCT 3’

-

R1: 5’ CGTCACCGCCGCAATCAACT 3’
Optimization of our Real time PCR was done by determining the optimal

concentration of primers, the optimal annealing temperature as well as by determining the
MgCl2 concentration.
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Specificity:

Specificity was tested for F1/R1 Oligonucleotide primers using template from
known bacteria; strains including Mycobacterium avium subspecies avium,
Mycobacterium tuberculosis (strain H37 Ra, non virulent) and Mycobacterium smegmatis
(strain MC2155).

Sensitivity:

MAP RNA was subjected to reverse transcription as described earlier. The standard
PCR was performed using Taq DNA polymerase Kit from eppendorf (Brinkman
instruments, Westbury, NY) as follows: PCR reactions consisted of PCR buffer (20mM
Tris-HCl pH8.0, 100mMKCl, 0.1 EDTA was added to a final concentration of 1X, 1mM
DTT, 50% Glycerol, 0.5% tween 20, Betaine (0.5mM), MgCl2 (5mM), forward and
reverse primers (F1/R1), 5ul cDNA and sterile distilled water for a final volume of 50ul
into sterile PCR tube. Tubes were incubated in iCycler system (BioRad, CA) for 5 min at
95oC as hot start step, followed by 40 cycles composed each of denaturation phase at
95oC for 30seconds, annealing phase at 60oC for 45 seconds, and extension phase at 72oC
for 1min, followed by an extension cycle for 10 min. Product was then purified using
PCR purification kit (Qiagen, CA). Concentration was determined by absorbance reading
at 260nm in nanodrop system (Nanodrop technologies, Wilmington, DE ) and subjected
to a series of dilutions (1:1, 1:10, 1:100, 1:1000, 1:10000, 1:100000and 1:1000000) with
14

an initial quantity of 33ng . Real time PCR was done using F1/R1 set of primers as
described in Table 3 after optimization.

Generating Standards for Real time RT_PCR:

These dilutions used in the sensitivity assay were later used as standards when
applied this method to clinical samples and cultures.

Melt Curve analysis:

Melt curve analysis was applied to all samples in order to exclude contamination in
our study where the nature of the amplified sequence can be confirmed.
The reaction was carried out as follow: the PCR tubes containing real time RT-PCR
products were incubated at 95oC for 1 minute followed by another minute at 60oC then 80
cycles with incubation at variable temperature for 10 seconds each, temperatures varied
between 65oC and 94oC with an increment of 0.5 oC.

Results

Real time RT-PCR targets and amplifies RNA templates signaling viability of the
15

template source. In this study we used RT-PCR based on oligonucleotide primers
derived from the IS900 sequence which is unique to MAP. All parameters and variables
involved in the isolation of RNA, synthesis of cDNA and PCR analysis were evaluated
and finally optimized to provide sensitive and maximum specificity outcome. Initially,
stock MAP culture was used to prepare MAP cultures in order to be used for RNA
extraction which in turn was used in the evaluations of all parameters.

RNA Extraction:

Due to the complexity of the cell wall of MAP and its absence in the MAP cell in
human clinical samples, different RNA isolation methods were evaluated. Initially, an
RNA isolation kit; RNA/DNA mini kit (Qiagen, CA); was used, the outcome was
disappointing due to the lower yield of isolated RNA (Figure 1, lane 1). However,
increasing the incubation period with lysosyme from 10 to 30 minutes and at 37 oC
instead of room temperature resulted in significant and quality increase in the isolated
RNA (Figure 1, lane 2). Further optimization of RNA isolation protocol had resulted in
the development of a modified procedure based on the combination of chemical lysis and
physical disruption of the MAP cells (Figure 1, lane 3). Physical disruption was achieved
using Fast-Prep Ribolyser (Qbiogene, CA). As shown in Figure 1, maximum RNA yield
was obtained when the latter RNA isolation protocol (combined chemical and physical
disruption treatment) was used (lane 4) compared to the protocol from Qiagen (Lane 1).
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Treatment with DNase for 30 min at 37oC resulted in complete DNA removal from
the RNA extracts. This was confirmed following direct analysis of the RNA solution by
agarose gel electrophoresis which resulted in absence of any DNA band (Figure 2). The
purity of the RNA extracts was also confirmed by performing PCR analysis on the RNA
extract without synthesis of cDNA template (Figure 3, lanes 1). The MAP target was
amplified when the cDNA step was included but not when the cDNA synthesis was
eliminated confirms the complete hydrolysis and removal of any DNA traces from the
RNA extracts (figure 4).
RNA was quantified using spectrophotometric measurement and then stored at _80
o

C until use.

Optimization of the RT-PCR:

Primer Design: MAP DNA consists of high percentage of G+C which is estimated
to be 69%. This characteristic favors formation of secondary structures and may lead to
false positive and lack of amplification. We used DNA folding software, available at
http://www.bioinfo.rpi.edu/~zukerm/, to determine the right annealing temperature to
minimize secondary structures of the template in order to design and evaluate
Oligonucleotide primers specific to MAP. The AV1/AV2 Oligonucleotide primers (Table
2) have been used successfully in our laboratory (3, 47, 51). Figure6 illustrates the
structure of IS900 under different temperatures. We designed new Oligonucleotide
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primers termed F1/R1 using the Primer 3 software available at
http://frodo.wi.mit.edu/cgi-bin/primer3. Blast analysis of the F1/R1 primers confirmed
the theoretical amplification of MAP template only and provided poor identity with other
genomes targets.
The optimal concentration of F1/R1 primers was determined by testing several
dilutions of each primer. In this study, primer concentrations ranged from 1 pmole/ul to
30pmole/ul were evaluated. As shown in Figure 7. Concentration of 6pmole/ul has been
identified to be the optimal and provided best amplification. Additionally, 6 pmole/ ul
resulted in significant reduction of primer dimerization even in negative controls (those
tunes lacking any templates).

Annealing temperature:

Following primers design and the estimation of appropriate annealing temperature,
we performed a temperature gradient assay on the MAP RNA template. As shown in
Figure 8, the annealing temperature ranged from 54 oC to 64 oC with an increment of 1.2
o

C. Optimum amplification was detected at 58 oC and 60 oC. Due to the nature of high

%G+C content of the MAP genome, we favored to use the 60 oC annealing temperature.
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Optimization of Magnesium ions:

The concentration of MgCl2 in PCR mixtures is known to play a major role in the
level of the assay sensitivity. In this study, MgCl2 concentrations ranged from 0 uM to 30
uM were evaluated. As shown in Figure 9, MgCl2 at 10 uM has been identified to provide
the optimal amplification signal in a 50 ul PCR reaction.

Over All RT-PCR Protocol:

Following the evaluation of all variables included in this RT-PCR assay, we have
developed and optimized protocol which is described in Table 3

Sensitivity of RT-PCR:

The optimized protocol described in Table 3 was employed on serial dilutions of
MAP cDNA ranged from 33ng to 0.000033ng in order to determine the lowest
concentration of RNA template needed for this assay. Figure 10 shows that MAP
template was detected in PCR mixtures containing 33ng/ul, 3.3ng/ul, 330pg and 33pg.
The lowest concentration of MAP template detected by this assay (33pg) corresponds to
61 copy of the IS900 gene. MAP contains between 14 to18 copies of the IS900 indicating
that this RT-PCR assay may be able to detect as low as 4 MAP cells per sample.
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Specificity of the RT-PCR:

In order to confirm the result of the Blast analysis of the Oligonucleotides primers
used in this study, several bacterial isolates (Table1) have been cultured and prepared for
extraction of RNA. RNA templates were then used for synthesis of cDNA and PCR
analysis. As expected, only MAP template was detected. There was no amplification
signal from all other microorganisms including the closely related M. avium subspecies
avium (Figures 5).

Clinical Evaluation of the RT-PCR assay

Since the ultimate application of this newly developed RT-PCR assay is to detect
viable MAP in clinical samples in hope it will aid in rapid identification of viable MAP in
clinical samples, we evaluated a total of 45 samples originated from subjects diagnosed
with Crohn’s disease, ulcerative colitis and NIBD including healthy controls. All samples
were blindly coded in order to conceal the identity and diagnosis of the sample. The
diagnosis was revealed following the conclusion of all experiments. Of the 45 samples,
17 were MAP cultures previously identified by acid-fast stain and nested PCR, 24 buffy
coat preparations from peripheral blood samples and 4 tissue homogenates from fresh
surgically removed tissue specimens. Tables 4 and 5 describe the clinical code of each
sample, diagnosis and the nature of the sample. The 17 MAP cultures originated from 13
patients with Crohn’s disease, 1 with Ulcerative colitis and 3 from NIBD subjects. The 24
20

buffy coats preparations consisted of 7 from Crohn’s disease patients, 2 from Ulcerative
colitis patients and 15 from NIBD individuals. All 4 tissue samples were removed from
two Crohn’s disease patients with each patient providing inflamed and normal tissue
samples. Interestingly, patients who provided tissue samples have also provided
peripheral blood samples.

MAP cultures:

Of the 17 cultures used in this study which originated from human sources, 12
(70%) were confirmed to have MAP by conventional nested PCR. All 17 cultures were
also evaluated using real time RT-PCR and 11 (65%) were also MAP positive.
Interestingly, the 11 MAP cultures confirmed by real time RT-PCR were also MAP
positive by conventional nested PCR (Table 4 a and b). Over all, 11/12 (92%) of the
MAP confirmed culture using nested PCR were positive by our real time RT-PCR.

Peripheral Blood Buffy coats:

A total of 24 Buffy coats preparations originated from 7 CD, 2 UC and 15 NIBD
subjects were evaluated using standard nested PCR and real time RT-PCR assay. By Real
time PCR, a total of 7/24 (29%) were confirmed to have viable MAP. Of the 7 MAP
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positive samples, 3/7 (43%) from CD, 2/2 (100%) from UC and 2/15 (13%) were from
NIBD patients. Using culture and nested PCR assay, a total of 9/24 (37%) was MAP
positive, specifically, 3/7 (43%) from CD patients, 2/2(100%) from UC patients, and 4/15
(26%) from NIBD subjects (Table 5a and b). It is important to note that both methods
confirmed viable MAP in the same three samples from CD patients. Similar outcome
were observed from samples originated from UC patients. However, of the 4 samples
from NIBD subjects that were MAP positive by culture and nested PCR, only one was
positive by our real time RT-PCR. The real time RT-PCR detected MAP in one NIBD
sample that was negative by culture and nested PCR.

Tissue samples:

A total of 4 tissue samples from 2 CD patients (1 inflamed and 1 non-inflamed
specimen from each patient) were evaluated by culture and nested PCR and real time RTPCR. Real time RT-PCR analysis detected MAP in 1/4 (25%) tissue samples. Results
from the culture and conventional nested PCR are still pending (table 6). The detection of
MAP in tissue by real time RT-PCR originated from inflamed lesion of CD patient. The
non-inflamed tissue from this CD patient was negative for MAP using real time RT-PCR.
Interestingly, blood sample from the same patient was also negative for MAP using real
time RT-PCR indicating a non-systemic state of MAP infection in this CD patient.
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Discussion

MAP has been confirmed to be the etiologic agent of JD. Its thermal tolerance,
resistance to alcohol and acid treatment and survival in pasteurized milk add more
characteristics to its pathogenicity and its virulence potential. As described earlier, MAP
role in Crohn’s disease pathogenesis has been suggested and vigorously debated.
Development of new methodology that facilitates rapid and consistent detection of MAP
in clinical samples from humans with Crohn’s disease may assist in the elucidation of
MAP role in Crohn’s disease. The development of RT-PCR assay is challenging due to
several reasons. Of which, working with RNA is extremely tedious and when the number
of bacterial cells such as MAP in clinical samples is naturally low, it adds to the
limitations of the assay. In this study, the RNA yield has been maximized and all
precautions were enforced in order to maximize cell lysis and minimize RNA
degradation. As shown earlier, a combination between chemical lysis and physical
disruption of MAP cells resulted in maximum recovery of MAP RNA. The use of
oligonucleotide primers derived from the IS900 of MAP added quality characteristic to
this RT-PCR assay. This is due to the presence of about 17 copies of the IS900 genes in a
single MAP cell which improves the sensitivity level by several folds.
The potential application of this RT-PCR assay in clinical diagnosis has been
validated in this study following the analysis of a total of 45 samples originated from
patients with Crohn’s disease, Ulcerative colitis and non-IBD subjects. In addition the
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coding system enforced here, the majority of these samples were also analyzed in our
laboratory for the presence of MAP using other methodology. Ultimately, this technology
will aid other conventional techniques such as culture media, despite the need for long
term incubation, in rapid detection of viable MAP. Most importantly, the application of
this technology will significantly aid the elucidation of MAP role in Crohn’s disease
pathogenesis. Regardless of the outcome, this test may aid in resolving the MAP debate
in Crohn’s disease etiology.
Culture can be delicate, as M. paratuberculosis is a slow growing and has extremely
long incubation times which can raise a contamination problem (2). Other diagnosis
methods had shown specificity and viability issues (11), a conventional RT-PCR is hard
to establish for detection of MAP in blood or tissue samples due to the small number of
bacterium recovered from these samples (14), development of new Real time RT- PCR
for detection of MAP in blood and tissue samples from Crohn’s disease patients may
open a new horizons in establishing a link between MAP and this debilitating disease as
well as in the diagnosis of the disease.
In this study, we have been able to extract MAP RNA from blood and tissue samples
using a mechanical disruption of the cells combined with chemical extraction, which goes
well with systemic nature of the disease (34, 47). The half life of RNA is markedly short
and the presence of RNase in the cell extract render the extraction even more delicate
(42), the use of RNase inhibitors in the extraction process and working at temperature
relatively low helped increasing the RNA recovery. To avoid DNA contamination and
ensure clean RNA, we treated the samples with DNase; RNA samples were used as
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negative control for the Real time PCR to check for DNA contamination.
We used Real time RT-PCR for it is very sensitive, does not require as much time
and to minimize the risk of contamination. Real-time RT-PCR has been recognized as an
accurate and sensitive method of quantifying mRNA transcripts (17, 50). This method
allowed us to detect accumulation of cDNA template in real time manner using SYBR
Green as an intercalating dye, rather than by conventional end-point analysis. Also there
is no need for post amplification procedures such as gel electrophoresis, analysis can then
be completed rapidly.
Our study was based on amplification of region of the IS900 sequence unique for
MAP using specific primers that amplify 165 base pair within the sequence as shown by
the specificity assay. The concentration of primers was determined with regard to
dimmers formation and optimal amplification of the template, in facts, primer dimmers
are a very common issue for real time RT-PCR (4, 5, 50). The annealing temperature was
determined with computational method that takes in consideration the percentage of base
pairs, the thermodynamic of the sequence and the possible secondary structures that
could be formed at each specific temperature, this had enable us to prevent any
nonspecific annealing of primers and helped reduce the generating of secondary
structures.
The sensitivity assay showed that our real time RT-PCR is able to detect as low as
61 copy of the IS900 sequence corresponding to 4 genome copies of MAP, which can be
of significance knowing that we are using cDNA as template and the number of
bacterium per sample is usually low, in addition to the short period of time that it takes to
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analyze the samples (less than 12 hours from the blood processing to real time RT-PCR
analysis). This can make the real time RT-PCR an alternative way for detection of MAP
in clinical samples from CD patients. Other studies using DNA based real time PCR were
able to detect lower copies of the genomes that were interested in, for example Danbing
Ke et all were able to detect 1 copy of the GBS genome (17). Our method is an RNA
based method so we can go in harmony with the goal of our study which is the detection
of viable MAP from clinical samples.
The application of our real time RT-PCR to buffy coat from inflammatory bowel
disease patients and individuals with non-inflammatory bowel disease (NIBD) and its
comparison with cultures of MAP from buffy coat and tissue samples from same patients
had shown a concordance of the results and therefore gave more incredibility to our
newly developed method. 54.5 % of IBD patients participating in this study are positive
for MAP but only 12.6 % of the NIBD were positive, the 12.6% of NIBD could be
exposed to MAP. In fact, MAP was isolated from water (41) and from pasteurized milk
(24), other studies had found Map in NIBD control with hyperthyroid and diarrhea (3).
Overall, this study show that real time RT-PCR could be an alternative way to detect
MAP in Crohn’s disease patients, this method has an answer for the viability, specificity
issues as well as for the long term incubation raised by other methods used to detect MAP
in clinical samples. The 54.5% MAP positive patients is a significant percentage, but
view the population studied, we still need to diagnose more samples in order to have a
confirmed association of MAP with Crohn’s disease.
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CHAPTER THREE: IFNGR1 GENE IS DOWNREGULATED IN
PATIENTS WITH CROHN’S DISEASE: A MYCOBACTERIAL
INFECTION?

Summary

In our laboratory, we previously demonstrated a possible downregulation in the
Interferon-gamma receptor gene (IFNGR1) in patients with active Crohn’s disease using
microarray chip analysis. In this study, Measurement of RNA by real time qRT-PCR
indicated a possible downregulation in 5/6 CD patients compared to 0/12 controls. Over
all, a total of 5/6 (83%) CD patients have MAP infection and downregulation in the
INFGR1 gene. The preliminary data suggest that downregulation in INFGR1 gene and
the detection of viable MAP together in CD patients provide yet the strongest evidence
toward the linkage between MAP and CD etiology.

27

Introduction

In normal immune response to microbial infection, cascades of signaling pathways
are initiated leading to activation of variety of types of immunity cells such as dendritic
cells and macrophages (60, 63). In the presence of an initiating antigenic stimulus,
antigen presenting cells (monocytes/ macrophages) produce IL-12 that stimulates TH-1
lymphocytes to increase their IFN-gamma production that will then acts on infected
macrophages to induce the production of proinflammatory cytokines, such as TNFalpha,
IL-6 and IL-1beta, which are the direct cause of inflammation in CD (1,2). This signaling
cascade leads macrophages to enhanced phagocytosis and intra-cellular killing of the
antigen producing infectious agent and so to the elimination of the antigenic stimulus.
However, if the immune system can not clear the antigen by this mechanism, either
because of the quantity of the antigen or genetically determined dysfunction in
production of cytokines and/or their respective receptors, a misdirected inflammatory
situation is seen such is the case of atypical tuberculosis (48), leprosy or any other
chronic infection with persisting antigenic burden. CD falls in the same category, in fact,
patients with this disease present abnormality in their immune system, but it is not known
yet whether these abnormalities are causes or results of the disease.
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CD and UC are known as important causes of gastrointestinal disease worldwide but
occurring more frequently in the united state, United Kingdom and Scandinavia (19), it is
known that Crohn’s disease affect 13 out of every 100,000 of the population in the UK
and other countries in Europe (59), over 500,000 carries the disease in the united state,
the incidence of Crohn’s disease is increasing worldwide (25). CD is not a sex or race
related, frequently affects people between the ages of 16 and 25, but it can also occur in
early childhood or later in life. CD can affect any part of the gastrointestinal tract
inflamed segments are discontinued in form of patches separated by normal bowel.
Inflammation is transmural resulting in fistula formation and the most common location
is the ileum and small bowel (32). CD Prevail in two distinct forms in which it is
analogous to two other mycobacterial diseases, leprosy and tuberculosis: a perforating
form and a non-perforating form (27, 33, 43). Leprosy and tuberculosis both manifest in
two distinct clinical forms: a contained form and an aggressive form (28, 61, 64). UC, in
contrast to CD, is a condition in which the inflammatory response is restricted to the
colon. Inflammation is limited to the mucosa and is continuous with ulceration and
edema. The etiology of any of these two disorders remain unknown, however granuloma
and pathologic manifestations in CD resemble aspects found in mycobacteria-caused
diseases such as tuberculosis, leprosy and paratuberculosis ( 16, 53, 8). MAP has been
reported as possible causative agent for CD, this possibility is increasingly gaining
momentum due to the recent findings, MAP was isolated from blood, tissue, milk of CD
patients (7, 46, 47). Early studies had shown that MAP is resistant to killing by
macrophages and/or Polymorphonuclear cells (44)
29

In 2001, three research groups had reported that three different mutations in NOD2/
CARD15 gene are associated exclusively with CD (31; 35, 49). the first susceptibility
gene for Crohn’s disease was then identified: NOD2 (nucleotide-binding oligomerization
domain) better known as CARD15 (Caspase activation recruitment domain) gene
annotated as NOD2/CARD15 is expressed as cytoplasmic protein in monocytes, and it is
comprised of N-terminus caspase-activation recruitment domains (CARD), a central
nucleotide- binding domain, and a C-terminus leucine-rich repeat (LRR) domain. When
The LRR domain senses muramyl dipeptide (MDP), the minimal motif of bacterial cell
wall peptidoglycan, CARD15 will activate NFkB. It is also known that NOD2/CARD15
is regulated by inflammatory cytokines, such as TNFalpha and IFN-gamma. Mutations in
NOD2/CARD15 were associated with CD, suggesting a role for intracellular pathogenhost interactions in the etiology of the disease.
Medical application of Microarray A study done by Whitney et al. provides a strong
support for the feasibility of RNA Microarray analysis of gene expression patterns in
peripheral blood as a basis for detection and diagnosis of disease in humans. This study
showed that the degree of variation in gene expression in the blood of healthy individuals
is smaller than the one seen in the individuals who had cancer or infection (62). An RNA
Microarray analysis of the expression profile of genes from CD and UC patients using the
buffy coats from peripheral blood had shown that 5630 genes (17% of total number of
genes) were differentially expressed in both IBD disorders 200 of which were genes
involved in immune response. Interestingly enough, the study showed that IFNGR1
(interferon-gamma receptor) gene, which encodes the ligand-binding chain of the IFN30

gamma receptor, is Downregulated exclusively in CD patients. In this study, we
evaluated the expression of IFNGR1 gene using quantitative real time RT-PCR in an
attempt to confirm the Microarray findings. Numerous studies had shown that
deficiencies in IFNGR1 gene are associated with familial disseminated atypical
mycobacterial infection and disseminated BCG infection. Individuals carrying these
deficiencies have an immunologic defect predisposing them to infection with
mycobacteria (38, 39, 40). If confirmed our finding will add a strong argument to the role
of MAP in CD etiology.
In this study, we intend to investigate blood samples from patients with CD, UC,
NIBD and healthy controls for the presence of viable MAP using real time RT-PCR
described in Chapter 1. The same clinical samples will be subjected to INFGR1 gene
analysis using qRT-PCR investigating possible downregulation as shown previously in
our lab using microarray chip analysis. Ultimately the study will provide for the first
time weather there is a link between the INFGR gene downregulation and susceptibility
to MAP infection in patients with active Crohn’s disease.
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Materials and methods

Patient Selection and Specimen Source

A total of 18 subjects consisting of 6 CD, 2 UC and 10 NIBD were included in this
study. Informed consent was obtained from the subjects in accordance with Institutional
Review Board regulations at the University of Florida, Gainesville VAMC, and the
University of Central Florida. The diagnosis of CD or UC was established on standard
clinical, endoscopic, histologic, and radiographic criteria (3). One whole blood sample
®

drawn into a K -EDTA sterile Vacutainer tube was collected from each subject. All
2

samples were coded and a self-reported health status and medication use of each subject
was recorded using a standardized questionnaire in order to minimize variables such as
age, gender, and medication interference.

Peripheral Blood Withdrawal and Processing

The samples were immediately processed in a class II biosafety cabinet. For buffy
coat extraction, the tubes were centrifuged at 3000 rpm for 10 min. The buffy coat layer
from each tube was transferred into an RNase-free tube containing 750 ul of RNA later
solution (Ambion, CA) and kept at 4oC until processing.
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RNA extraction:

Total RNA was isolated from Buffy Coats using modified protocol from
RNAqueous-4PCR Kit (Ambion, CA).whole blood was centrifuged at 3000 rpm for 10
min, buffy coat layer was then transferred into a 2ml RNase free tube containing 750 ul
of RNA later then processed immediately by centrifugation at 13000rpm for 1 minute ,
cell pellet was treated with lysing solution and Nucleic acid was separated using phenol
chlorophorm the aqueous phase was then transferred to new RNase free 2ml tube RNA
was washed, eluted then treated with DNase I for 30 min at 37oC. The RNA purity and
integrity was assessed by Agarose gel and stored at -80oC to be reverse-transcribed.

cDNA Analysis:

The RNA isolated from buffy coats was subjected to reverse transcription using the
super script III kit (Envitrogen, CA) as described in Chapter 1. The cDNA was then used
for evaluation by real time RT-PCR.

Quantitative Real time RT-PCR:

A real time RT-PCR was optimized and normalized to evaluate quantitatively the
gene IFNGR1 using syber green and MyIQ system (BioRad, CA), 12.5ul of SYBR Green
mix were added to MgCl2 (5mM), Betaine (0.5mM), primers (6 mM), 2.5ul of cDNA,
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and sterile distilled water to a final volume of 25ul into sterile PCR tube and were
incubated at 95oC for 5 min as hot start step followed by 40 cycles : 20 sec denaturation
step at 95oC then 30 sec annealing step at 60oC were the Fluorescence was captured for
analysis. Primers were designed with Primer 3 software and blasted against the gene bank
data base for specificity; we used Primers MI1/MI2 that amplifies 200bP from the 5’ end
of the gene. The IFNGR1 gene is GC rich,
MI1: 5’CCCCTTGTCATGCAGGGTGTGA 3’
MI2: 5’ CAGGGACCTGTGGCATGATCTGG 3’
To avoid secondary structures, Betaine was added as described in Chapter 1. Bactine was used in order to normalize the reaction as reference gene and the results were
analyzed.

IFN gamma ELISA Test:

Interferon gamma was evaluated in sera and plasma from patients with CD, UC and
from NIBD individuals using an interferon gamma based ELISA kit (R&D Systems,
Minneapolis, MN). Assay Diluent was added to each well in the ELISA plate, followed
by Standards, samples, and control as described by the manufacturer. Microtiter plates
were incubated for 2 hours at room temperature, followed by washes as described in the
kit. IFN-γ Conjugate was added to each well. The plates were then incubated for 2 hours
at room temperature, washed again and then incubated in the dark for 30 min. in the
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presence of substrate solution. The optical density of each well was determined using a
microplate reader set to 450 nm and 570 nm. Reading at 570nm was then subtracted from
reading at 450nm in order to correct optical imperfections in the plate.

Results
To evaluate the expression of IFNGR1 gene, RNA samples isolated from buffy coats
of 6 CD patients and 2 UC subjects were analyzed against RNA from buffy coats of 10
NIBD individuals (4 of them were healthy individuals). A quantitative real time RT-PCR
was developed and optimized for this purpose. The results were compared to microarray
outcomes from previous study done on the same samples. cDNA of IFNGR1 gene was
sequenced for mutation analysis.

Quantitative real time RT-PCR:

Isolated RNA was evaluated using quantitative real time RT-PCR assay developed
and optimized for this purpose. The assay was normalized using β-actine gene as
reference gene. Primers used were specific for IFNGR1 gene and amplify a 200 base pair
from the 5’ end of the gene and specificity of sequence amplified was assisted using melt
curve analysis. As shown in Table 8 a and b, all 10 (100%) NIBD subjects including 4
healthy controls expressed normal and expected level of IFNGR1 gene. Normal gene
expression was also observed in both (100%) patients with UC. However, out of the 6
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CD patients, 5 (83%) showed defect in the INFGR1 gene expression suggesting a
possible downregulation. Only one CD (17%) patient showed normal INFGR1 gene
expression. Our findings also confirmed the microarray analysis data which showed that
the IFNGR1 gene is exclusively downregulated in CD patients. This could give a strong
insight to the role of Map in CD since IFNGR1 defect was associated with Mycobacterial
infection (12, 36, 37, 38). Interestingly, evaluation of buffy coat from the patient who
expressed IFNGR1 gene normally, with culture and nested PCR as well as with real time
RT-PCR confirmed presence of MAP in blood samples of this patient (table9). An
IFNGR1 gene mutation analysis for samples from this patient is undergoing for further
investigating the gene and its role in MAP infection.

Evaluation of levels of IFN-γ in Clinical Sera:

Along with Downregulation analysis, sera from CD and UC patients as well as from
NIBD individuals were analyzed to evaluate the level of IFN-γ in blood. Table 10
illustrates data from an ELISA analysis and as expected shows clear increase in
concentration of IFN-γ in sera from the majority of CD patients (5/6; 83%), 1/2 (50%) of
UC patients and 0/5 of healthy individuals.
One UC and one CD patients presented a normal level of IFN-γ this could be
explained by the antimycobacterial treatment they followed. Interestingly, the patients
with higher concentration of IFN-γ had downregulated IFNGR1 gene.
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Discussion

IFNGR1 gene encodes the ligand binding chain alpha of the IFN-γ receptor. As
shown in this study, using real time RT-PCR, IFNGR1 was downregulated exclusively in
patients with CD but not in UC patients. This data confirm what we had found earlier by
microarray analysis (figure15). And correlate with theory that associate MAP with CD (7,
33, 28, 46). Downregulation of IFNGR1 gene may cause a failure of IFN-γ to up-regulate
production of TNF-α by macrophages hence disregulation of antigen processing and
presentation (48) even if IFN-γ concentration in plasma from patient with CD and UC is
relatively higher as shown by data from ELISA Table 10
In 1996, Newport et all revealed in a case study that deficiency in IFNGR1
expression due to mutation lead to a defect in immune response in patients carrying this
mutation predisposing them to mycobacterial infection. Our finding, correlate with
Newport study and suggest strongly a host susceptibility condition for establishing a
mycobacterial infection. It also support why UC patients having MAP exposure don’t
develop the same clinical manifestations as CD patients or don’t respond to antimycobacterial treatments. Preliminary data from the ELISA measurement of interferon
gamma level in clinical sera were not surprising. It is well known that INF-γ level is
elevated in inflammatory bowel disease patients. The significance of this observation is
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important in order to associate that with downregulation of the gene encoding for the
receptor of INF-γ. Although, this study is still in the early stages, it clearly indicates the
need for a large scale investigation of the susceptibility of the INFGR1 gene in CD
patients. We believe we may just have discovered the genetic susceptibility factor in
hosts with Crohn’s disease.
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CHAPTER FOUR: GENERAL DISCUSSION

Association of MAP with CD has been subject of vigorous debate among scientists,
Evidence supporting a link between Map and Crohn’s disease such as higher detection
rates of Map by PCR and culture in clinical samples from Crohn’s patients compared
with controls; detection of anti-MAP IgG antibodies in sera from CD patients and antiMap antibiotic therapy resulting in remission, or significant improvements, in many
cases. The general opinion among the scientific community is that there isn’t enough
evidence to prove or deny the role of MAP in CD etiology; nevertheless, the hypothesis is
still valid. The etiology of CD had been controversial; many agents were reported to have
a role in this etiology; thus, Crohn’s disease is now believed to have a multifactorial
etiology with involvement of genetic predisposition (NOD2 mutations), environmental
factors (infectious agent, diet or smoking), and abnormal inflammatory response (25).
Isolation and culture of MAP from clinical samples from CD patients have been
tried in the past. The outcome depended significantly on the technology used and the
specimen selection and processing. We previously reported the isolation of MAP from
full-thickness tissue samples obtained from CD patients, from Breast milk and from
blood samples from CD patients following short term incubation in mycobacterial growth
indicator tube (MGIT) culture media (46,47). In all reports, MAP presence in the culture
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was evaluated using IS900-based PCR.
As reported by Chiodini, MAP in CD clinical samples is in Spheroplastic form (cellwall deficient form) which is different from those in animals with JD this contribute
greatly to the challenges faced when culturing MAP from Clinical samples from CD
patients (7); using technology designed for isolation of bacillary form of MAP as in JD
sources may not be applicable to that in human with CD. That alone will play a major
factor in the outcome of the study. There is a possibility that exposure to MAP could
occur through environmental fecal contamination or from the milk or blood from JDinfected animals which can explain isolation of MAP from NIBD individuals (20, 23, 24,
25).
Development of Real time RT-PCR that detect IS900 MAP specific sequence will
eventually aid other conventional techniques such as culture media, despite the need for
long term incubation, in rapid detection of viable MAP in clinical samples. Most
importantly, the application of this technology will significantly aid the elucidation of
MAP role in Crohn’s disease pathogenesis. Regardless of the outcome, this test may aid
in resolving the MAP debate in Crohn’s disease etiology.
The preliminary data of this study along with microarray data suggest that
downregulation in INFGR1 gene and the detection of viable MAP together in CD
patients provide yet the strongest evidence toward the linkage between MAP and CD
etiology. It also supports why UC patients having MAP exposure don’t develop the same
clinical manifestations as CD patients or don’t respond to anti-mycobacterial treatments.
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APPENDIX A: FIGURES
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Figure1: comparison of RNA yield with Qiagen protocol, Modified Qiagen protocol
and combination of Mechanical and chemical extraction.
RNA samples were mixed with sample loading buffer and analyzed on 1% agarose gel
electrophoresis. M: marker, lane 1 corresponds to RNA extraction from manufacturer
protocol, Lane 2 corresponds to RNA extraction from modified manufacturer method,
and lane3 & 4 correspond to RNA extraction using combination of physical disruption
and chemical extraction.
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Figure 2: Evaluation of RNA extracts for the presence of DNA using DNase
treatment using agarose gel electrophoresis.
RNA extracts isolated using our modified procedure was treated with DNase for 30 min
at 37o C.
Band 1 corresponds to 23S ribosomal RNA; Band 2 corresponds to 16S ribosomal RNA
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Figure3: Evaluation of RNA extracts for the presence of DNA in the presence and
M
1
absence of DNase using PCR analysis.

2

3

M: corresponds to marker. Lane 1 corresponds to negative controls; Lane 2 corresponds
to PCR product using RNA without DNase treatment, Lane 3 corresponds to PCR using
RNA with DNase treatment as template.
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Figure 4: Evaluation of the RNA extracts for the presence of MAP DNA in the
presence and absence of cDNA synthesis step.
M corresponds to Marker, Lane 5&6 corresponds to RNA extracts treated with DNase
and then subjected to cDNA synthesis before RT-PCR was employed. Lane 3 same as 3
except the cDNA synthesis step was eliminated. Lanes 1 and 2 corresponds to negative
control where templates were not included in the PCR amplification. Lane 7: corresponds
to positive control where DNA template was used.
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4

5

6

Figure 5 Evaluation of our real-time RT-PCR for specific detection of MAP. RNA
templates from 4 different microorganisms were subjected to real-time RT- PCR analysis
using our developed protocol. A corresponds to graphical illustration of the real time
PCR and B corresponds to agarose gel electrophoresis of PCR products shown in figure
5-I, the green color corresponds to tunes containing MAP cDNA. The blue, red and
yellow correspond respectively to MAV, MTB and MSM. IN Figure 5-II, lane 6
corresponds to tunes containing MAP cDNA, lane 1 and 2 correspond to negative
controls, lane 3 corresponds to MSM, lane 4 corresponds to MTB and lane 5 correspond
to MAV.
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A

B

C
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Figure 6: Effect of annealing Temperature on secondary structure formation in
IS900 sequence.
Alignment of IS 900 sequence: A: at 55oC, B: at 60oC, C: at 69oC
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Figure 7: Optimization of the concentration of Oligonucleotide primers used in this
study. A serial dilution of F/R1 primers ranged from (0 to 33 pmol/ul; lanes 2-8) were
evaluated by real time RT-PCR. Curve7 correspond to a primer concentration of
6pmole/ul M: corresponds to Marker, Lane 1 corresponds to negative control.
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8

9

Figure 8: evaluation of the annealing temperature used in this study:
figure8-I corresponds to Real time RT-PCR Graph, where curves a to h : corresponds to
reaction with annealing temperature that varies from 54oC to 64oC,curve I corresponds to
negative control. In figure 8-II, M corresponds to marker, lane 1 corresponds to negative
control, and lane 2 to 9 correspond to reactions with annealing temperature from 54oC to
64oC
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Figure 9: Optimization of the concentration of MgCl2 used in this study.
A serial concentrations of MgCl2 from (0 to30 mM; lanes 1-7) were evaluated by real
time RT-PCR. M: corresponds to Marker.
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7
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Figure 10: Evaluation of our real-time RT-PCR for sensitive detection of MAP
RNA.
Dilution series from 1:10 to 1:1000000 of RNA templates with a starting
concentration of 33ng/ul were subjected to real-time PCR analysis using our
developed protocol: Figure10-I) corresponds to graphical illustration of the real time
PCR. Letters from a to g corresponds respectively to tunes containing MAP RNA in
respectively 1 to 1:1000000 dilutions. Figure10-II) corresponds to agarose gel
electrophoresis of PCR products shown in figure 10-I, lanes 1 to 7 corresponds to
tunes containing MAP RNA , lane 8 correspond to negative control, lane 1 to 7
correspond to PCR products from RNA dilutions with 1 been RNA with no dilution
and 7 been RNA with the higher dilution. M corresponds to marker.
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Cycle
Figure11: Representative figure for evaluation of samples from patients using real
time RT-PCR
Each sample is represented by different color according to its position on the plate.
Standards were used in this assay as well as controls.
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40%
35%
30%
25%

Total positive
samples

20%
15%
10%
5%
0%
Real time RT-PCR

Culture & nested PCR

Figure 12: Detection of MAP in human samples by Real time RT-PCR (12hours)
and culture confirmed by nested PCR (12weeks).
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Total MAP
Positive
samples

120%
100%
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40%
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20%
0%
CD

UC

NIBD

: Real time RT-PCR
: Culture and nested PCR

Figure13: Evaluation of MAP positive samples from CD, UC and NIBD individuals
using real time RT-PCR compared to culture confirmed by nested PCR
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Figure 14: Biological themes predicted by MeV with EASE microarray analysis
software
We found that 17% (5630 genes) of the total number of genes was differentially
expressed in both IBD disorders compared to the reference pooled sample. These genes
were distributed mainly within four biological themes classified as cellular processes
(38%), physiological processes (26%), intracellular genes (18%), and genes involved in
metabolism (18%). (This figure was obtained from Doctor Romero PhD thesis)
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Figure 15: variation in some of the immune response gene expression patterns
including IFNGR1 in human white blood cells.
The differentially expressed genes IFNGR1 is boxed in red and indicated by a plus sign
next to the red box. Each element is red, green, black, or gray. Black elements have a log
ratio (Cy5/Cy3) of 0, while green elements have a log ratio of less than 0 and red
elements have a log ratio greater than 0. The further the ratio from 0, the brighter the
element is. Gray elements have invalid values and are not used in any analysis.
(This figure was obtained from Doctor Romero PhD thesis)
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III)

Figure 16: Representative figure for IFNGR1 gene expression analysis using real
time RT_PCR.
I) correspond to real time RT-PCR graph, II) correspond to representative gel picture and
III) correspond to melt curve which show 2 peaks, one for IFNGR1 around 81oC and
another one around 90oC for beta-Actine.
N: correspond to negative controls, P corresponds to positive control, and M corresponds
to marker, in the graph each sample is represented by distinguished color
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Figure17: graph illustrating quantitative real time RT-PCR data
The higher the ∆Ct the lower is the expression.
Figures 1 to 10 correspond to NIBD samples, figures 11 & 12 correspond to UC samples
and figures 13 to 18 correspond to CD samples
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APPENDIX B: TABLES
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Table1: List of microorganisms used in the study.

Microorganism

Strain

Mycobacterium avium subspecies

ATCC Ben

paratuberculosis
Mycobacterium avium subspecies avium

Clinical isolate strain LM1

Mycobacterium tuberculosis

ATCC 25177

Mycobacterium smegmatis

MC2155
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Table2. Oligonucleotide primers used in this study.

Nucleotide sequence

Primer’s name

Reference

5’ GTT-CGG-GGC-CGT-CGC-TTA-GG-3'

P90

(31, 33, 35)

5’ GAG-GTC-GAT-CGC-CCA-CGT-GA-3’

P91

5’ ATGTGGTTGCTGTGTTGGATGG 3’

AV1

5’CCGCCGCAATCAACTCCAG 3’

AV2

5’ CACGTCGGCGTGGTCGTCT 3’

F1

In this study

5’ CGTCACCGCCGCAATCAACT 3’

R1

In this study
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Table 3: Optimized protocols for PCR analysis used in this study:

Conditions
Thermal cycler
Reaction duration
Reaction volume
Analysis
Amount analyzed
Target/size
Primers/concentration.
MgCl2 conc.
PCR buffer
dNTP concentration
DNA polymerase
PCR parameters

conventional Nested PCR
iCycler
2X 3 h
50 ul
gel electrophoresis
5 ul (10%)
IS900 /(400 bp)
P90, 91/(12 pmole/ul each)
AV1/AV2 (10pmole/ul)
4 ul (5mM)
5ul [200mM Tris-HCl (pH8.4),
500mM KCl]
1ul (10mM)
HiFi Taq polymerase (5U/ul)
hot start: 5 min/95 oC
36 cycles: 45 s/95 oC
45 s/62 oC
120 s/72 oC
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Real time RT-PCR
My IQ system
1:00 h
25 ul
real time fluorescence
25 ul (100%)
IS900 /(165 bp)
F1/R1/(6 pmole/ul each)
1ul (5mM)
12.5ul (Buffer, dNTP
& enzyme all mixed
in one tube)
hot start: 3 min/95ojC
40 cycles: 10 s/95 oC
30 s/60 oC

Table 4A: Analysis of culture samples For MAP by real time RT-PCR versus
culture and nested PCR.

Sample Code

Diagnosis

Real time RT-PCR

Culture& Nested PCR

B2

CD

Positive

Positive

B3

CD

Positive

Positive

R14A

CD

Positive

Positive

R14B

CD

Positive

Positive

B20

CD

Positive

Positive

R33B

CD

Negative

Negative

UCF6

CD

Positive

Positive

UCF7

CD

Positive

Positive

UCF8

CD

Positive

Positive

B34

CD

Positive

Positive

B50

CD

Positive

Positive

B55

CD

Negative

Positive

R60B

CD

Negative

Negative

Total

13

10/13(77%)

11/13(85%)

B39

UC

Negative

Negative

Total

1

0/1

0/1

R6

NIBD

Negative

Negative

B30

NIBD

Negative

Negative

R36

NIBD

Positive

Positive

Total

3

1/3 (33%)

1/3 (33%)
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Table 4B: Over all summaries of MAP detection in culture samples by direct
analysis using real time RT-PCR versus culture and nested PCR.

Patients

MAP positive by

MAP positive by

Diagnosis

real time RT-PCR

culture & nested PCR

CD

10/13(77%)

11/13(84%)

UC

0/1(0%)

0/1(0%)

NIBD

1/3(33%)

1/3(33%)

Total

11/17(65%)

12/17(70%)
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Table5A: Analysis of peripheral blood buffy coat samples for Map detection by real
time RT-PCR versus culture and nested PCR.

Sample code
BS77
BS78
BS82
BS88
BS92
BS96
BS99
Total
BS94
BS95
Total
BS72
Bs73
BS74
BS75
BS76
BS79
BS83
BS84
BS85
BS86
BS87
Total
NS
MC
Md
Bn
Total

Diagnosis
CD
CD
CD
CD
CD
CD
CD
7
UC
UC
2
NIBD
NIBD
NIBD
NIBD
NIBD
NIBD
NIBD
NIBD
NIBD
NIBD
NIBD
11
Healthy
Healthy
Healthy
Healthy
4

Real time RT-PCRc
Negative
Negative
Positive
Positive
Positive
Negative
Negative
3/7(42%)
Positive
Positive
2/2(100%)
Positive
Negative
Positive
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
2/11(18%)
Negative
Negative
Negative
Negative
0/4 (0%)
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Culture & Nested PCRd
Negative
Negative
Positive
Positive
Positive
Negative
Negative
3/7(42%)
Positive
Positive
2/2(100%)
Positive
Negative
Negative
Negative
Negative
Negative
Positive
Positive
Negative
Positive
Negative
4/11(36%)
Negative
Negative
Negative
Negative
0/4 (0%)

CD: corresponds to patients with Crohn’s disease
UC: corresponds to patients with ulcerative colitis
NIBD: corresponds to individuals with non-inflammatory bowel diseases.
RT-PCR was performed using R1/F1 oligonucleotide primers
d
buffy coats were inoculated into MGIT (MYCOBACTERIA GROWTH INDICATOR
TUBE ) culture media, incubated for a minimum of 12 weeks and then confirmed for
MAP using nested PCR based on the p90/91 oligonucleotide primers.
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Table 5B: Over all summaries of MAP detection in peripheral blood buffy coat
samples by direct analysis using real time RT-PCR versus culture and nested PCR.

Patients

MAP Positive

MAP Positive by

Real time RT-PCR

diagnosis

by Real time RT-

Culture & Nested

versus culture & Nested

PCR

PCR

PCR

3/7(42%)

3/7(42%)

100%

2/2(100%)

2/2(100%)

100%

5/9(55%)

5/9(55%)

2/11(13%)

4/11(26%)

50%

0/4(0%)

0/4(0%)

100%

2/15(13%)

4/15(26%)

IBD
CD

UC
Total
NIBD
Healthy
Total
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Table 6: Analysis of fresh tissue samples for MAP detection using real time RT-PCR
versus culture and nested PCR.

Sample

Diagnosis

Real time RT-

Culture & Nested

PCR

PCR

positive

Pending

negative

Pending

Code
R61A

CD, inflamed
tissue

R61B

CD, noninflamed

R62A

CD, inflamed

Negative

Pending

R62B

CD, non-

negative

Pending

inflamed
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Table7: Genes with Differences in the Expression Levels in each subtype of IBD
Disorder. (This table was used from doctor Romero PhD thesis).

______________________________________________________________________
Gene Bank

Description

Expression in

Expression in

CD patients

UC patients

______________________________________________________________________
AA083407

Tripartite motif-containing 22

No change

Downregulated

AA476221

Unnamed protein product

Downregulated

No change

AA495985

Small inducible cytokine

Downregulated

Upregulated

Downregulated

No change

A18 precursor (CCL18)
AI123732

EBV-induced G protein-coupled
receptor 2 (EBI2)

AA281497

Interferon-gamma receptor alpha 1

Downregulated

No change

R47893

Small inducible cytokine A3

Downregulated

Upregulated

precursor (CCL3)
AA454646

Lymphotoxin-beta receptor

No change

Upregulated

AI298976

Lymphotactin precursor (XCL1)

Downregulated

No change
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Table 8 a: Analysis of Buffy coats from peripheral blood of patients to
evaluate IFNGR1 gene expression using quantitative real time RT-PCR
Sample
code

microarray
Diagnosis

RT-PCR
∆Ct

Gene expression
BS 25
BS 26
BS 27

NIBD

BS86

3.23

Normal

Normal

4.38

Normal

Normal

5.62

Normal

No data

Normal

No data

4.61
6.28

No data

-0.53

Normal

No data

4.33

Normal

No data

2.46

Normal

No data

2.61

Normal

Normal

NIBD
NIBD
NIBD
NIBD

BS 33

UC

BS47

UC

BS 37

Normal

NIBD

BS87

BS 35

Normal

Healthy

BS54

BS85

4.42

Healthy

Healthy

BS84

Normal
Healthy

BS 28

BS83

Gene expression

No change

5.33

No change

No change
No change

Down-regulated

6.09
14.31

Down-regulated

11.56

Down-regulated

Down-regulated

10.19

Down-regulated

Down-regulated

13.78

Down-regulated

No change

1.87

No change

Down-regulated

CD
CD

BS 42

CD

BS 43

CD

BS61

CD

BS88

CD

No change

11.31
77

downregulated

Table 8b: overall Summary of IFNGR1 gene expression in CD patients and Non CD
individuals.

Patients Diagnosis

down-regulated gene

NIBD

0/10(0%)

UC

0/2 (0%)

CD

5/6(83%)
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Table9: Evaluation of IFNGR1 gene expression in with regard to MAP diagnosis in
samples from CD, UC and NIBD subjects.

Sample's code
BS25
BS54
BS85
BS87
BS33
BS47
BS35
BS37
BS42
BS43
BS88

Diagnosis

Q RT-PCR
Analysis

NIBD

normal

NIBD

normal

NIBD

normal

NIBD

normal

UC

normal

UC

normal

CD

downregulated

CD

downregulated

CD

downregulated

CD

downregulated

CD

normal
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MAP
Diagnosis
negative
negative
negative
negative
positive
negative
negative
positive
positive
positive
positive

Table 10: Evaluation of level of IFN-γ in sera from peripheral blood of CD, UC and
NIBD subjects using ELISA:

Sample

Diagnosis

mean OD reading

IFN-γ concentration

NS

Healthy

0.09

12.5

MC

Healthy

0.077

6

Md

Healthy

0.083

9

Bn

Healthy

0.075

5

BS84

Healthy

0.067

1

BS33

UC

0.111

23

BS47

UC

0.083

9

R27

CD

0.087

11

R28

CD

0.785

360

BS35

CD

0.108

21.5

BS43

CD

0.11

22.5

BS44

CD

0.259

97
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Cut off value
Normal
Normal
Normal
Normal
Normal
Elevated
Normal
Normal
Elevated
Elevated
Elevated
Elevated
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